GSK (NYSE:GSK) Issues FY 2024 Earnings Guidance

GSK (NYSE:GSK) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.710-1.740 for the period, compared to the consensus EPS estimate of 4.060. The company issued revenue guidance of $40.9 billion-$41.7 billion, compared to the consensus revenue estimate of $41.5 billion.

GSK Trading Up 0.3 %

GSK stock traded up $0.11 during mid-day trading on Friday, hitting $36.87. The company’s stock had a trading volume of 6,876,973 shares, compared to its average volume of 3,858,042. GSK has a one year low of $33.67 and a one year high of $45.92. The stock has a market cap of $76.41 billion, a PE ratio of 24.10, a P/E/G ratio of 1.23 and a beta of 0.65. The company has a 50 day moving average of $40.78 and a 200-day moving average of $41.05. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $9.95 billion during the quarter, compared to analysts’ expectations of $9.49 billion. GSK had a return on equity of 51.23% and a net margin of 7.97%. On average, research analysts anticipate that GSK will post 4.08 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.26%. The ex-dividend date is Friday, November 15th. GSK’s dividend payout ratio is 98.70%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on GSK shares. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday. Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Finally, Barclays raised GSK to a “hold” rating in a report on Tuesday, August 27th. Five analysts have rated the stock with a hold rating, one has assigned a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $50.00.

Insiders Place Their Bets

In other news, major shareholder Plc Gsk acquired 2,791,930 shares of GSK stock in a transaction dated Friday, September 27th. The stock was purchased at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 10.00% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.